A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

BACKGROUND: In phase I studies, poziotinib has shown meaningful efficacy against various types of cancers. This phase 2 study aimed to investigate the efficacy and safety of poziotinib in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M‐HNSCC). METHODS: Overall, 49 patients wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Ji Hyun, Heo, Seong Gu, Ahn, Beung‐Chul, Hong, Min Hee, Cho, Byoung Chul, Lim, Sun Min, Kim, Hye Ryun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Researcher
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525103/
https://www.ncbi.nlm.nih.gov/pubmed/34528763
http://dx.doi.org/10.1002/cam4.4231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525103/
https://www.ncbi.nlm.nih.gov/pubmed/34528763
http://dx.doi.org/10.1002/cam4.4231

Ejemplares similares